Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

Technology appraisal guidance
Reference number: TA865
Published: 08 February 2023

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 137 KB)

Published:

08 February 2023
Register of interests (PDF 138 KB)

Published:

08 February 2023

Final draft guidance

Final draft guidance
Final appraisal document (PDF 287 KB)

Published:

22 December 2022
Public committee slides (PDF 741 KB)

Published:

22 December 2022
Committee papers (PDF 317 KB)

Published:

22 December 2022

Draft guidance: 1

Draft guidance: 1
Appraisal consultation document (PDF version) (PDF 295 KB)

Published:

11 October 2022
Appraisal consultation document (online commenting)
Committee papers (PDF 10.35 MB)

Published:

11 October 2022
Public committee slides (PDF 902 KB)

Published:

11 October 2022

Invitation to participate

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 253 KB)

Published:

13 January 2022
Equality impact assessment (Scoping) (PDF 121 KB)

Published:

13 January 2022
Final stakeholder list (PDF 163 KB)

Published:

13 January 2022
Final scope (PDF 202 KB)

Published:

13 January 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 189 KB)

Published:

30 September 2020
Draft scope post referral (PDF 161 KB)

Published:

30 September 2020